Hodgkin Lymphoma

Hodgkin lymphoma is a cancer of the lymphatic system, a network of tissues and organs that help the body fight infection. It commonly affects adolescents and young adults (AYA). Survival rates today are over 95% overall, however, many survivors suffer long-term side effects from these treatments. Of these, the most concerning include heart disease and the development of secondary cancers later in life. Given these risks, it is essential to not only cure the disease but also to minimize the long-term impact of treatment.

SUPPORT HODGKIN LYMPHOMA RESEARCH opens in a new tab

COG’s Work in Hodgkin Lymphoma

Children’s Oncology Group’s (COG) Hodgkin Lymphoma Committee incorporates biologically targeted therapies to maintain high cure rates at initial diagnosis. The Committee tailors the use of radiation therapy and certain chemotherapy based on a patient’s disease burden at diagnosis and their response to early treatment, allowing for a more personalized care approach.

The Committee works in partnership with groups at the National Cancer Trials Network (NCTN) to ensure novel therapies can be tested and available to AYA with Hodgkin lymphoma at the same time as adults. In parallel, the Committee evaluates the impact of new treatment strategies on patients’ quality of life. For patients with a relapse or recurrence of Hodgkin lymphoma, the Committee is developing approaches to minimize the use of autologous stem cell transplant when possible.

Back to all Clinical Focus Areas

Hodgkin Lymphoma: Key Statistics

  • > 0 %

    Survival rate for children and adolescents with advanced stage Hodgkin lymphoma.

  • > 2 years old

    The age approved for use of the antibody drug conjugate Brentuximab vedotin thanks to a COG trial (AHOD1331) that resulted in FDA approval.

Recent Publications

Discover More Publications

Through a high-risk Hodgkin lymphoma study in partnership with SWOG Cancer Research Network, we identified a new standard of care with our adult colleagues and got our adolescent and young adult patients access to a new therapy potentially a decade earlier than they would have otherwise.

Read More

COG Member Institutions

COG’s 220+ member institutions study and treat children and adolescents with cancer across a global network. These sites support patients from diagnosis through treatment and beyond, connecting families to clinical trials and specialized care closer to home.

Use our interactive map to find a COG member institution near you.

Find a Member Location

News from COG

As the world’s largest pediatric cancer research network, COG drives breakthroughs in treatment and improves outcomes for children with cancer. Explore the latest news and stories from across our global community.

SEE ALL NEWS

Additional Resource Links:

The future for children with Hodgkin lymphoma is shaped by today’s research.

Your support helps fuel discoveries that deepen understanding and move us closer to cures and more effective treatments.

Support Hodgkin Lymphoma Research opens in a new tab